{"filing":{"accession_number":"0001193125-26-337964","cik":"0002044725","ticker":"EVMN","company_name":"Evommune, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"evmn-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526337964/evmn-20260806.htm"},"events":[{"id":25605,"run_id":23240,"accession_number":"0001193125-26-337964","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a standard earnings release disclosing Q2 2026 financial results for Evommune, Inc., filed under Item 2.02 (Results of Operations and Financial Condition). The press release includes unaudited condensed consolidated statements of operations and balance sheets, showing net loss of $32.2 million and $53.9 million for Q2 and H1 2026 respectively, along with cash position of $288.0 million as of June 30, 2026. The disclosure is material to investors assessing the company's financial condition and cash runway through 2028.","company_name":"Evommune, Inc.","ticker":"EVMN","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26485,"accession_number":"0001193125-26-337964","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard earnings release disclosing Q2 2026 financial results for Evommune, Inc., filed under Item 2.02 (Results of Operations and Financial Condition). The press release includes unaudited condensed consolidated statements of operations and balance sheets, showing net loss of $32.2 million and $53.9 million for Q2 and H1 2026 respectively, along with cash position of $288.0 million as of June 30, 2026. The disclosure is material to investors assessing the company's financial condition and cash runway through 2028.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:16:32.268670+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26485,"accession_number":"0001193125-26-337964","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard earnings release disclosing Q2 2026 financial results for Evommune, Inc., filed under Item 2.02 (Results of Operations and Financial Condition). The press release includes unaudited condensed consolidated statements of operations and balance sheets, showing net loss of $32.2 million and $53.9 million for Q2 and H1 2026 respectively, along with cash position of $288.0 million as of June 30, 2026. The disclosure is material to investors assessing the company's financial condition and cash runway through 2028.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:16:32.268670+00:00","company_name":"Evommune, Inc.","ticker":"EVMN","filing_date":"2026-08-06"}]}